TickerTalks
Browse all tickers →
TickerTalks›$IMVT
IMIMVT

Immunovant, Inc.

$IMVT·$8.2B·Biotechnology·Healthcare
$41.20-6.0%YTD+53.9%1Y+178.0%
Mentions · last 7 days
2026-08-20: 5 posts2026-08-21: 9 posts2026-08-22: 2 posts58+4%
Price updated 2d ago·X counts updated 8d ago
IMIMVT
$IMVTImmunovant, Inc.
$41.20-5.98%58 posts+4%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $IMVT, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Driven by hypeWinding up for a moveAI verdict · as of 2026-08-25

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Up 191% in twelve months on the batoclimab FcRn autoimmune thesis — trading at new 52-week highs with a fresh law-firm investigation lurking.

Immunovant is a clinical-stage biotech developing batoclimab, a fully human monoclonal antibody that blocks the FcRn receptor — a mechanism relevant to a range of autoimmune conditions including myasthenia gravis, thyroid eye disease, and warm autoimmune hemolytic anemia. The stock is up 191% over the trailing year and 54% year-to-date, sitting at 93% of its 52-week range.

  • The company has no revenue and quarterly losses of $95-117M (Q1 FY26: -$95M FCF), so this is entirely a clinical-milestone story
  • Analyst FY26 revenue estimate is $10.5M growing to $52.9M by FY28, $513.7M by FY29, and $1.05B by FY30 — the ramp assumes commercial launch, and 2029 is where the model tips to profitability
  • On August 19 a Kuehn Law press release encouraged IMVT investors to contact the firm — that's the standard language for an investigation into potential securities-law violations; the specific concern isn't named in the release, but it's an overhang worth flagging
  • Insider signal is minimal: Melanie Gloria sold 3,056 shares at $44.16 for $135K on August 20 — one small officer sale, not decisive but not zero
  • The four EPS surprise pattern shows misses: -19%, -23%, +15%, -1% — the losses are consistently deeper than modeled, which is normal for pre-revenue biotech but flags cash-burn watch
  • Roivant Sciences (ROIV) CEO reportedly saying 'Pharma calls about IMVT all the time' — implies takeover interest, though this is unattributed X commentary
  • Beta 0.81 — surprisingly muted for a biotech, but the FcRn-class franchise has real commercial validation from ARGX (argenx) already generating billions in revenue

The risk-reward is asymmetric but binary — this is priced for the ARGX-like commercial scenario, and any Ph3 disappointment resets hard.

Agrees with X sentimentX frames $40 as a launch pad for a 40→340 setup like historic biotech runs. Aspirational but not crazy given the class validation from ARGX; the class-action inquiry is a specific incremental risk X hasn't weighted.

What to watch: The Q2 FY27 print on November 9 needs to include readable Ph3 timeline updates — data-readout dates are what turn narrative into confirmed thesis or break it.

On the calendar: 2026-11-09 — Q2 FY27 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment5 posts analyzed · as of 2026-07-03

Immunovant (IMVT) is being discussed with $ROIV CEO Gline noting phone calls from Pharma about IMVT all the time. Community frames IMVT at $40 as launch pad like prior 40->340 setups. The tone is aggressive long positioning into the biotech catalyst.

Read the AI verdict + X sentiment for $IMVT

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Develops FcRn antibody inhibitors that reduce pathogenic IgG antibodies for treating autoimmune and inflammatory diseases.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $IMVT.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $IMVT

Neutral — Develops FcRn antibody inhibitors that reduce pathogenic IgG antibodies for treating autoimmune and inflammatory diseases; limited read-through from biotechnology macro dynamics to this specific revenue mix.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+51.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-12.5How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-62.5%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-6.4%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-68.2%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 6, 2026$-0.75$-0.63-19.3%
Q1 2026May 20, 2026$-0.73$-0.59-23.3%
Q4 2025Feb 6, 2026$-0.61$-0.72+15.3%
Q3 2025Nov 10, 2025$-0.73$-0.72-1.4%
Next earningsMon, Nov 9·consensus EPS $-0.73

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q4 FY26$0———$-0.73$-95.1M
Q3 FY26$0———$-0.61$-92.3M
Q2 FY26$0———$-0.73$-102.5M
Q1 FY26$0———$-0.71$-117.4M

Forward consensus

6-year forecast · up to 9 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$10.5M$10.5M – $10.5M-$2.61-$2.85 – -$2.488
FY27$6.6M$6.6M – $6.6M-$2.65-$3.03 – -$2.469
FY28$52.9M$52.9M – $52.9M-$2.58-$2.84 – -$2.378
FY29$513.7M$513.7M – $513.7M-$1.33-$3.34 – -$0.029
FY30$1.1B$1.1B – $1.1B$0.79$0.79 – $0.794
FY31$1.6B$1.6B – $1.6B$2.81$2.81 – $2.813

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.0×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.86%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+2.4%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+36.6%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellAug 28Atul PandeDirector1.5K sh$65KSellAug 20Melanie GloriaCOO3.1K sh$135KSellJul 24Atul PandeDirector1.5K sh$60KSellJul 23Tiago GiraoCFO6.8K sh$263KSellJul 23Jay S StoutCTO2.9K sh$111KSellJul 8Melanie GloriaCOO2.0K sh$81KSellJul 8Van Tuyl ChristopherChief Legal Officer1.2K sh$48KSellJul 8Jay S StoutCTO3.5K sh$138KSellJul 2Eric VenkerCEO3.1K sh$119KSellJun 26Atul PandeDirector1.5K sh$57K
1–10 of 27
+ 23 other (11 awards · 10 exempts · 2 returns) in window

See when $IMVT insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

No material 8-K / SC 13D / S-3 / 424B5 filings in the last 180 days.

+ 8 other (2 earnings 8-Ks · 2 proxys · 1 13G · 1 10-Q) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Algert Global LLC Raises Position in Immunovant, Inc. $IMVTdefenseworld.net·3d agoKuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firmprnewswire.com·11d agoImmunovant (NASDAQ:IMVT) Sets New 12-Month High – Still a Buy?defenseworld.net·12d agoImmunovant, Inc. (IMVT) Q1 2027 Earnings Call Transcriptseekingalpha.com·24d agoImmunovant Q1 Earnings Call Highlightsmarketbeat.com·24d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALT$AURA$IOVA$NWBO$SLS$AMLX$ABCL
Voices on X · top 3 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport